enVVeno Medical Corp (NVNO) is the subject of an amended Schedule 13D in which prior reporting holders Braeden Lichti and Northstrive Fund II LP report that they have fully exited their positions in the company’s common stock. The cover pages state that each reporting person now beneficially owns 0 shares, representing 0.00% of the outstanding common stock, with no voting or dispositive power.
Lichti sold all of his previously owned shares of enVVeno Medical Corp common stock on September 11, 2026. Northstrive Fund II LP sold all of its previously owned shares from September 11, 2026 to September 14, 2026. The amendment is designated as a final “exit” filing for both reporting persons, superseding an earlier Schedule 13D filed on February 20, 2026.
enVVeno Medical Corp (NVNO) director Francis Duhay reported selling 11 shares of common stock on September 11, 2026 at a reported price of $11.21 per share in an open-market or private transaction. The sale was completed pursuant to a Rule 10b5-1 trading plan adopted in June 2025, and he directly holds 2,351 shares after the transaction.
enVVeno Medical Corp (NVNO) received a Form 144 notice from director Francis G. Duhay covering a proposed sale of restricted common stock under Rule 144. The notice states an intention to sell 11 shares of common stock through broker The Charles Schwab Corporation on NASDAQ.
The filing reports an aggregate market value of $123.00 for the planned sale and indicates that these 11 shares were acquired in an open market purchase on December 31, 2024.
enVVeno Medical Corporation (NVNO) filed a replacement Form S-3 shelf registration allowing it to offer up to $100,000,000 of mixed securities, including common stock, preferred stock, warrants, debt securities and units. Under Rule 415(a)(6), this shelf carries forward $57,331,170 of unsold securities from a 2023 registration, which will terminate by the earlier of this shelf’s effectiveness or February 19, 2027.
The company is a late-stage medical device developer focused on the enVVe System, a transcatheter replacement venous valve for severe deep Chronic Venous Insufficiency. In April 2026, the FDA granted an Investigational Device Exemption for the pivotal TAVVE study, which will enroll 230 patients in two stages at up to 40 U.S. sites.
enVVeno ended 2025 with $28.2 million of cash and investments and held $21.5 million as of June 30, 2026. It expects quarterly cash burn to rise from approximately $3–4 million to $4–5 million in the second half of 2026, providing runway into the third quarter of 2027, and discloses that it will need to raise additional capital. Net proceeds from future shelf takedowns are expected to fund continued enVVe System development and general corporate purposes.
Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 24,605 shares of enVVeno Medical Corporation common stock through warrants, representing 3.5% of the outstanding class. The percentage is based on 682,722 shares of common stock outstanding as of July 28, 2026 and assumes exercise of all 24,605 warrants held by the Master Fund. The warrants are immediately exercisable but are subject to a 9.99% Beneficial Ownership Limitation, which currently permits full exercise. Each reporting person has shared voting and dispositive power over the 24,605 underlying shares and reports ownership of 5 percent or less of the class.
enVVeno Medical Corporation develops the enVVe System, a first-in-class transcatheter replacement venous valve for patients with severe Chronic Venous Insufficiency. In April 2026, the FDA granted Investigational Device Exemption (IDE) approval for the TAVVE pivotal study, a two-stage trial of 230 patients at up to 40 U.S. sites that could support an FDA post-marketing submission one year after the 220th enrollment in stage two.
For the quarter ended June 30, 2026, enVVeno reported a net loss of $3.6 million, down from $6.7 million a year earlier, as operating expenses fell on lower VenoValve study costs and reduced stock-based compensation. Six-month net loss was $7.4 million versus $11.2 million. Cash and investments totaled $21.5 million with working capital of $20.2 million, and the company states these resources should fund operations into the third quarter of 2027, though it expects quarterly cash burn to rise to $4–$5 million in the second half of 2026 and acknowledges it will need additional capital over time.
enVVeno Medical Corporation disclosed that on July 14, 2026 it issued an investor presentation that may be used in meetings with investors, analysts and others. The presentation is provided as Exhibit 99.1 and is furnished under Regulation FD, not deemed filed or incorporated by reference under the Exchange Act except if specifically referenced.
enVVeno Medical Corp director Francis Duhay sold a small block of company stock in a pre-planned trade. On June 11, 2026, he completed an open-market sale of 140 shares of common stock at $10.305 per share. After this transaction, he directly holds 2,362 shares of enVVeno Medical Corp common stock. The sale was executed under a Rule 10b5-1 trading plan that he adopted in June 2025, indicating the trade was pre-scheduled rather than a discretionary decision based on recent developments.
enVVeno Medical Corporation reports a Schedule 13G/A disclosing that Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. each beneficially own 9.99% of Common Stock. The filing states the ownership percentages are based on 667,669 outstanding shares as of May 1, 2026 and assume exercise of Warrants for 18,267 shares, constrained by a Beneficial Ownership Limitation.
The Master Fund directly holds 50,258 shares and 24,605 Warrants; Perceptive Advisors is investment manager and Joseph Edelman is managing member. Shared voting and dispositive power is reported for 68,525 shares.